Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
13,423 total articles
Obagi Medical, part of Waldencast plc (NASDAQ: WALD), disclosed encouraging interim clinical and real-world data for its new skincare innovations: the NU-GEN Cellular Renewal Serum and Saypha® MagIQ™ injectable filler, presented at the Music City Symposium for Cosmetic Advances & Laser Education (SCALE). Data from over 300 clinical sites validate t…
Safe Pro Group Inc. (NASDAQ: SPAI) announced exceptional first quarter 2026 financial results with record revenue of $1.22 million, a 560% increase from the prior year, driven by a 2,400% surge in AI-powered product sales. The company’s AI solutions, including the NODE and NODE-X edge processing systems and the SPOTD threat detection platform, demo…
INmune Bio released Phase 2 MINDFuL trial results demonstrating positive trends for XPro™ (pegipanermin) in Alzheimer's patients with inflammatory biomarkers. The findings, published in NPJ Dementia, showed consistent benefit across multiple clinical and biomarker endpoints with no amyloid-related imaging abnormalities, validating the inflammation-…
CG Oncology reported positive interim results from its Phase 2 CORE-008 Cohort CX trial evaluating the combination of cretostimogene grenadenorepvec with gemcitabine in patients with high-risk non-muscle invasive bladder cancer (NMIBC) who are BCG-exposed or BCG-unresponsive. The study showed high complete response rates, strong high-grade event-fr…
aTyr Pharma announced its Q1 2026 financial results and outlined a clear regulatory path forward for efzofitimod in pulmonary sarcoidosis. Following a Type C FDA meeting, the company plans to submit an IND in June 2026 for a global Phase 3 trial targeting patients with chronic pulmonary sarcoidosis and restrictive lung disease. Enrollment is on tra…
Cocrystal Pharma has completed enrollment in the first cohort of its Phase 1b human challenge study for CDI-988, an oral protease inhibitor targeting norovirus and coronaviruses. The company received FDA Fast Track designation for CDI-988, enabling potential accelerated development. Additionally, it secured the initial $225,000 SBIR NIH grant for i…
Dycom Industries, Inc., a leading specialty contracting service provider in telecommunications and utilities, announced it will hold its fiscal 2027 first quarter earnings call on May 27, 2026. A press release with the quarter's financial results will be issued earlier that day, followed by a conference call and webcast to discuss performance and a…
Perma-Fix Environmental Services, Inc. announced it has priced an underwritten public offering of approximately 2.29 million shares of common stock at $8.75 per share to raise gross proceeds of about $20 million. The company plans to use the net proceeds to fund capacity upgrades at its Northwest Richland facility, continue research and development…
UroGen Pharma reported that its investigational drug UGN-103 achieved a 94.5% six-month durability of response in the ongoing Phase 3 UTOPIA trial for patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). The results align closely with the performance of ZUSDURI, the company's FDA-approved treatment i…
LifeMD, Inc., a leading virtual primary care platform, announced that its management will participate in the LD Micro Invitational XVI Conference and the B. Riley Securities 26th Annual Investor Conference in May 2026. The company aims to engage with investors through presentations and one-on-one meetings to discuss its telemedicine offerings and g…
BioCardia, Inc. reported Q1 2026 financial results and highlighted regulatory progress for its CardiAMP Cell Therapy in ischemic heart failure. PMDA in Japan acknowledged sufficient safety and efficacy evidence for market clearance, moving the therapy closer to approval. The FDA expressed support for continuing the CardiAMP HF II confirmatory trial…
Our Bond, Inc., an AI-powered preventative personal security platform company, provided a business update and reported Q1 2026 financial results with modest revenue growth of 4.36% to $2.3 million. The company expanded its global footprint and enterprise deployments across varied sectors including retail, telecommunications, financial services, and…
Trio Petroleum Corp. is reminding shareholders to vote in advance of its May 21, 2026 Annual Meeting. The company emphasizes the importance of achieving quorum to approve proposals that facilitate its strategy of disciplined expansion through acquisitions and operational execution. Trio highlights its improved financial position and focus on long-t…
LanzaTech Global, Inc. announced a registered direct offering of 2 million common stock shares to institutional investors, aiming to raise approximately $20 million before expenses. The proceeds will be used for general corporate purposes. The offering is expected to close around May 18, 2026, under an SEC-approved shelf registration. LanzaTech spe…
Belite Bio announced an oral presentation at Retina China 2026 to showcase positive topline results from its Phase 3 DRAGON trial evaluating tinlarebant, an oral therapy for Stargardt disease type 1 (STGD1). Tinlarebant demonstrated a significant 35.7% reduction in atrophic retinal lesion growth and was well tolerated. The company is progressing re…
GT Biopharma reported Q1 2026 financial results highlighting ongoing Phase 1 trials for GTB-3650 in hematologic malignancies and GTB-5550 in multiple solid tumor types. The company has approximately $9 million in cash, expected to fund operations through Q4 2026. Despite increased SG&A expenses leading to a larger net loss compared to last year, th…
Lifeward Ltd. announced its Q1 2026 financial results, highlighting the successful closing of its acquisition of Oratech alongside a $10 million financing. The acquisition adds $6.5 million in cash and advances Lifeward's Protein Oral Delivery platform, including the lead asset ORMD-0801 oral insulin set for Phase 2 trials. The company also acquire…
Galectin Therapeutics disclosed its Q1 2026 financial results, highlighting ongoing advancement of its lead drug belapectin in the NAVIGATE Phase 2b/3 trial for patients with MASH cirrhosis and portal hypertension. The company reported promising biomarker and liver stiffness data supporting belapectin's potential to reduce fibrosis progression. It …
Globavend Holdings Limited, a US-listed e-commerce logistics provider, has agreed to acquire a 70% stake in Loomi Entertainment Group, a digital entertainment company specializing in AI-powered short-form video content aimed at Southeast Asian audiences. This strategic move marks Globavend's entry into the digital entertainment sector to diversify …
Immuneering Corporation announced strong Phase 2a clinical data for its pancreatic cancer drug candidate atebimetinib combined with chemotherapy, which will be presented at the 2026 ASCO Annual Meeting. The pivotal Phase 3 MAPKeeper 301 trial is now recruiting with first dosing on track for mid-2026. Financially, the company ended Q1 2026 with $198…
Bread Financial Holdings, Inc. provided a performance update for April 2026, reporting a 2.0% year-over-year increase in average credit card and other loans. The company noted improvements with net principal losses decreasing to $105 million and the net principal loss rate dropping to 7.09%, alongside a delinquency rate reduction to 5.34%. These fi…
Phillips Edison & Company, a leading owner and operator of grocery-anchored neighborhood shopping centers, has appointed industry veteran Dan Sutherland as Vice President of Acquisitions for the West region. With over 20 years of experience and a strong track record in retail real estate transactions, Sutherland will focus on sourcing and executing…
LM Funding America, a US-based Bitcoin treasury and mining company, reported first quarter 2026 results with record energized hashrate and highest monthly Bitcoin production in company history. Despite mining increased Bitcoin volumes, total revenue fell 11.1% year-over-year due to declining Bitcoin prices. The company incurred a significant net lo…
BriaCell Therapeutics announces the development of Bria-OVA+, a next-generation personalized immunotherapy targeting ovarian cancer, building on their Phase 2 success in metastatic breast cancer. The candidate leverages an enhanced immune-stimulating cell-based platform, aiming to address the significant unmet medical need in ovarian cancer, the de…
Annovis Bio reports strong progress in its Phase 3 Alzheimer's disease trial with 85% patient enrollment and initiation of a Parkinson’s disease open-label extension study at 40% enrollment. The company anticipates NDA submissions for buntanetap as a symptomatic treatment in early 2027 and as a disease-modifying therapy in early 2028. Financially, …
